Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
LAKE FOREST, Ill., Feb. 06, 2017 -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Wednesday, March 1, 2017 outlining the fourth quarter and full year 2016 results.
In addition, the Company will host a conference call at 10:00 am ET on the same day to discuss its fourth quarter and full year 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and +1 (270) 823-1530 for international callers. The conference ID is 62420433. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.
A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.
About Akorn:
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.
Investors/Media: Stephanie Carrington ICR, Inc. (646) 277-1282 [email protected]
